<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is an auto-immune <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> for which anti-thrombotic medication is necessary for long-term management to reduce thrombotic risk or pregnancy morbidity </plain></SENT>
<SENT sid="1" pm="."><plain>Choosing the type of pharmacological treatment, i.e. the intensity and duration of anticoagulation, depends on the severity of an individual's APS and the risk of <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>This article reviews the current literature on anticoagulation therapy, provides recommendations on when to initiate therapy, and suggests possible alternatives for optimisation of management </plain></SENT>
</text></document>